

## Research Article

# Efficacy and Safety of Eplerenone for Treating Chronic Kidney Disease: A Meta-Analysis

## Honglei Hu<sup>1</sup>,<sup>1</sup> Mengdie Cao,<sup>2</sup> Yao Sun,<sup>1</sup> Xingqian Jin,<sup>1</sup> Xiaodong Zhao,<sup>1</sup> and Xiangguo Cong<sup>1</sup>

<sup>1</sup>Department of Endocrinology, Shandong Zibo Central Hospital, Zibo 255000, China <sup>2</sup>Department of Endocrinology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou 215000, China

Correspondence should be addressed to Xiangguo Cong; cxg136999@126.com

Received 9 December 2022; Revised 8 February 2023; Accepted 1 March 2023; Published 9 March 2023

Academic Editor: Tomohiro Katsuya

Copyright © 2023 Honglei Hu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. In recent years, a large amount of clinical evidence and animal experiments have demonstrated the unique advantages of mineralocorticoid receptor antagonists (MRA) for treating chronic kidney disease (CKD). Aims. Accordingly, the present study aimed to systematically assess the second-generation selective MRAs eplerenone's safety and effectiveness for treating CKD. Methods. Four databases (PubMed, The Cochrane Library, Embase, and Web of Science) were searched for randomized controlled trials (RCT) correlated with eplerenone for treating CKD up to September 21, 2022. By complying with the inclusion and exclusion criteria, literature screening, and data extraction were conducted. Results. A total of 19 randomized controlled articles involving 4501 cases were covered. As suggested from the meta-analysis, significant differences were reported with the 24-h urine protein (MD = -42.23, 95% confidence interval [CI] = -76.72 to -7.73, P = 0.02), urinary albumin-creatinine ratio (UACR) (MD = -23.57, 95% CI = -29.28 to -17.86, P < 0.00001), the systolic blood pressure (SBP) (MD = -2.73, 95% CI = -4.86 to -0.59, P = 0.01), and eGFR (MD = -1.56, 95% CI = -2.78 to -0.34, P = 0.01) in the subgroup of eplerenone vs placebo. The subgroups of eplerenone vs placebo (MD = 0.13, 95% CI = 0.07 to 0.18, P < 0.00001) and eplerenone vs thiazide diuretic (MD = 0.18, 95% CI = 0.13 to 0.23, P < 0.00001) showed the significantly increased potassium levels. However, no statistical significance was reported between the eplerenone treatment groups and the control in the effect exerted by serum creatinine (MD=0.03, 95% CI = -0.01 to 0.07, P = 0.12) and diastolic blood pressure (DBP) (MD = 0.11, 95% CI = -0.41 to 0.63, P = 0.68). Furthermore, significant risks of hyperkalemia were reported in the eplerenone group (K<sup>+</sup>  $\ge$  5.5 mmol/l, RR = 1.70, 95%) CI = 1.35 to 2.13, P = < 0.00001;  $K + \ge 6.0$  mmol/l, RR = 1.61, 95% CIs = 1.06 to 2.44, P = 0.02), respectively. Conclusions. Eplerenone has beneficial effects on CKD by reducing urinary protein and the systolic blood pressure, but it also elevates the risk of hyperkalemia.

## 1. Introduction

CKD has become a globally recognized serious public health problem and a major factor contributing to the global burden of disease [1]. At present, the common drugs for CKD treatment consist of ACEI or AREB, which are capable of reducing urine protein and protecting the kidneys by blocking the renin-angiotensin-aldosterone system. SGLT-2i and GLP-1 analogues offered unique renal protection in diabetic nephropathy as well. Besides, MRAs, acting on mineralocorticoid receptors and suppressing excessive MR activation, could be an effective supplementary treatment for the existing clinical treatment of CKD cases [2]. Though several nonsteroidal MRAs achieving fewer side effects were developed and studied, they have not yet achieved extensive clinical applications. Eplerenone, the second-generation selective MRAs, should be considered a treatment for CKD [3, 4]. Therefore, the clinical application value of CKD will be comprehensively analysed from the clinical indicators closely related to the prognosis of CKD.

Hence, we conducted this meta-analysis to systematically assess the second-generation selective MRAs eplerenone's safety and effectiveness for treating CKD.

#### 2. Materials and Methods

2.1. Search Strategy. This meta-analysis protocol was performed in strict accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statements [5]. A total of 4 databases (PubMed, The Cochrane Library, Embase, and Web of Science) were searched up to September 21, 2022. The search terms covered "chronic kidney disease," "mineralocorticoid receptor antagonists," and "eplerenone."

#### 2.2. Inclusion and Exclusion Criteria

- 2.2.1. Inclusion Criteria
- (1) Participants.
  - (a) Adult male and nonpregnant female cases diagnosed with CKD (GFR > 30 ml/min/1.73 m<sup>2</sup>, serum potassium (K<sup>+</sup>)  $\leq$  5.0 mmol/l in 24 h before randomization) [1].
  - (b) Study cases may or may not have had a history of mild to moderate hypertension (SBP/DBP ≥ 140/ 90 mmHg), whereas only SBP/DBP ≤ 180/ 110 mmHg and without symptomatic hypotension were eligible.
  - (c) All articles were randomized controlled trials (RCTs) and crossover articles, assessing the effect of eplerenone with or without ACEI/ARB, in comparison with placebo or active control as a treatment for CKD for at least 4 weeks.

(2) Outcome measures. The endpoints covered were 24-h proteinuria, urinary albumin-creatinine ratio (UACR), estimated glomerular filtration rate (eGFR), serum creatinine, systolic blood pressure (SBP), diastolic blood pressure (DBP), and serum potassium levels. Adverse effects (e.g., events of hyperkalemia,  $K^+ \ge 5.5 \text{ mmol/l}$  and  $\ge 6.0 \text{ mmol/l}$ ).

2.2.2. Exclusion Criteria. (1) Duplicate published or incomplete literature; (2) meta-reviews, case reports, letters, meeting abstracts, etc.; (3) articles that cannot obtain the full text and the required outcome indicators; (4) nonhuman clinical trials and non-RCTs of eplerenone therapy; and (5) articles of CKD with an unclear diagnosis or combined with other diseases.

2.3. Study Selection and Data Extraction. By complying with the inclusion and exclusion criteria, two authors screened the title and abstract of the respective literature, and read the full text of the literature that met the criteria. Lastly, the data were extracted independently. Any disagreement between the 2 authors was addressed by consensus or by a third investigator. Data collection consisted of first authors, years and countries of literature, study designs, the No. of cases involved, interventions, study duration, as well as the endpoints of the study.

2.4. Evaluation of the Risk of Bias. Evaluation of the risk of bias was performed by the two authors with the use of the Cochrane Collaboration's risk of bias evaluation kit, covering the following items: (1) selective report (report bias); (2) incomplete outcome information (attribution bias); (3) blinding of outcome evaluation (detection bias); (4) blinding of participants and personnel (performance bias); (5) allocation concealment (selection bias); (6) random sequence generation (selection bias); and (7) other biases.

2.5. Statistical Analysis. Our study employed RevMan 5.3 software (the Cochrane Collaboration, UK) for this metaanalysis. With the use of the 95% confidence interval (CI) and mean difference (MD), the analysis was conducted on the continuous variable. Besides, the dichotomous variable had the expression of relative risk (RR) with a 95% CI. The  $I^2$  statistic was adopted for evaluating statistical heterogeneity, which was not considered to be significant when  $I^2 < 50\%$  and P > 0.1, and fixed-effect model analyses were conducted for the data pooling; otherwise, the randomeffect model was chosen. A sensitivity investigation was carried out for evaluating the individual trial's contribution to the pooled effect through the sequential omission of the respective trial. The graphic data were presented through forest plots. And funnel plots were employed for testing publication biases.

#### 3. Results

*3.1. Search Results.* After the retrieval of existing literature, 1558 eligible articles were obtained in total, and 19 articles [6–24] were covered here. The study selection is depicted in Figure 1.

3.2. Characteristics of Eligible Articles and Quality Evaluation. The final analysis involved 19 RCTs, published from 2002 to 2021, with a total of 4501 subjects. A total of 2296 cases were covered in the treatment group, and the control group involved 2205 cases. Among the 19 articles, the smallest one of the studies contained 15 cases, and the most involved 2127 cases. Intervention periods ranged from 8 weeks to 42 months. A summary of the basic characteristics of the literature is presented in Table 1.

The Cochrane risk bias evaluation tool evaluates the quality exhibited by the involved literature, as illustrated in Figure 2. In the 19 articles involved, random sequence generation was all clear (100%), and 7 articles (36.8%) were assigned with adequate hiding. For the blinding design, 13 articles (68.5%) were suggested to be double-blind, 1 (5.2%) was single-blind, and 5 articles (26.3%) were nonblind. Among the 19 articles, 18 articles (94.7%) had clear results, one study lacked partial data, and except for 2 articles, which had other biases as impacted by the small sample size, the other articles were unclear about the bias of selective reporting and other biases.



FIGURE 1: Flowchart of the literature search process.

#### 3.3. Efficacy Outcomes

3.3.1. Effect of Treatment on 24-h Proteinuria and UACR. The involved articles fell into subgroups by different control drugs (placebo/thiazide diuretic/RAS blockers/CCBs), the results of the meta-analysis included:

3.3.2. The Effect of Treatment on 24-h Proteinuria. The effect of eplerenone on 24-h proteinuria was evaluated in 7 articles with 286 participants in total. No significant heterogeneity was identified between the articles involved in the subgroups ( $\chi^2 = 6.11$ , P = 0.41,  $I^2 = 2\%$ ), and the fixed effects model was adopted. A significant reduction was identified in the subgroup of eplerenone vs placebo (MD = -42.23, 95% CI = -76.72 to -7.73, P = 0.02),whereas no significant effect was identified compared with thiazide diuretic (MD = -9.0, 95% CI = -109.09 to 91.09, P = 0.86) and RAS blockers (MD = 22.24, 95% CI = -82.35 to 126.83, P = 0.68). Given all of the mentioned analysis, the total effect is that the 24-h proteinuria was significantly reduced in the eplerenone treatment groups than the control (MD = -33.30, 95% CI = -64.43 to -2.16, P = 0.04) (Figure 3(a)).

3.3.3. The Effect of Treatment on UACR. Twelve articles showed the changes in UACR between the eplerenone treatment groups and the control. After the heterogeneity analysis, one study with high heterogeneity was excluded for further analysis, and the other 11 articles (n = 1348) did not

indicate significant heterogeneity between the subgroups ( $\chi^2 = 9.44$ , P = 0.49,  $I^2 = 0\%$ ). Significant reductions were identified in the subgroups of eplerenone vs placebo (MD = -23.57, 95% CI = -29.28 to -17.86, P < 0.00001) and eplerenone vs CCBs (MD = -22.50, 95% CI = -24.35 to -20.56, P < 0.00001), whereas no significant effect was identified in comparison with thiazide diuretic (MD = -84.54, 95% CI = -203.23 to 34.15, P = 0.16) and RAS blockers (MD = -9.12, 95% CI = -30.98 to 12.74, P = 0.41). Given all the mentioned analysis, the total effect was that the UACR was significantly reduced in the eplerenone treatment groups as compared with the control (MD = -22.53, 95% CI = -24.28 to -20.78, P < 0.00001) (Figure 3(b)).

3.3.4. Effect of Treatment on eGFR. Sixteen articles (n = 4082) showed the changes in eGFR between the eplerenone treatment groups and the control. In the subgroup that compared eplerenone vs RAS blockers, no significant change was shown (MD = 0.63, 95% CI = -1.54 to 2.81, P = 0.57), while significant changes were observed in the subgroups of eplerenone vs placebo (MD = -1.56, 95% CI = -2.78 to -0.34, P = 0.01) and eplerenone vs thiazide diuretic (MD = 6.89, 95% CI = 5.19 to 8.60, P < 0.00001). In a pooled analysis of all 16 articles, there was high heterogeneity within the subgroups ( $Chi^2 = 70.07$ , P < 0.00001,  $I^2 = 79\%$ ), and the effect of eplerenone treatment on eGFR was significant compared with the control (MD = 1.18, 95% CI = 0.27 to 2.08, P = 0.01) (Figure 4(a)).

					No.			
	Author	Year	Country	Study design	of patients included (Male/Female)	Interventions	Study duration	Endpoints
	Epstein et al	2006	USA	Parallel RCT	T: 177 (116/61) C: 91 (50/41)	T: EPL + ACEI C: Placebo + ACEI	12 weeks	BP, UACR, eGFR incidence of hyperkalemia
	Joffe et al	2007	USA	Cross-over RCT	T: 8 C: 8	T: EPL + ACEI C: HCTZ + ACEI	6 weeks	BP, 24h-proteinuria, creatinine, estimated creatinine clearance, potassium, the incidence of hyperkalemia
	Kovarik et al	2021	Austria	Parallel RCT	T: 7 (7/0) C: 8 (5/3)	T: EPL + ACEI C: Placebo + ACEI	10 weeks	BP, UACR, eGFR
	Boesby et al	2013	Denmark	Parallel RCT	T: 22 C: 24	T: EPL + ACEI/ARB C: Placebo + ACEI/ ARB	24 weeks	BP, 24h-proteinuria, estimated creatinine clearance, eGFR, creatinine, potassium incidence of hyperkalemia
	Jacobsen et al	2020	Denmark	Parallel RCT	T: 70 (53/17) C: 70 (53/17)	T: EPL C: Placebo	26 weeks	BP, UACR, eGFR, potassium incidence of hyperkalemia
	Mokadem et al	2020	Egypt	Parallel RCT	T: 25 (15/10) C: 25 (13/12)	T: EPL C: ACEI	24 weeks	BP, UACR, eGFR, creatinine, potassium incidence of hyperkalemia
1	Karashima et al	2016	Japan	Parallel RCT	T: 25 (17/8) C: 25 (17/8)	T: EPL + ARB C: HCTZ + ARB	48 weeks	BP, UACR, eGFR, potassium
	Epstein et al	2002	USA	Parallel RCT	T: 74 C: 74	T: EPL C: ACEI	24 weeks	BP, UACR, incidence of hyperkalemia
	Sawai et al	2017	Japan	Parallel RCT	T: 98 (49/49) C: 97 (49/48)	T: EPL C:Thiazide diuretic	8 weeks	BP, UACR, creatinine, eGFR, potassium incidence of hyperkalemia
	Ando et al	2014	Japan	Parallel RCT	T: 162 (114/48) C: 152 (100/52)	T: EPL + ACEI/ARB C: Placebo + ACEI/ ARB	52 weeks	BP, UACR, eGFR, potassium incidence of hyperkalemia
	Boesby et al	2011	Denmark	Cross-over RCT	T: 40 C: 40	T: EPL + ACEI/ARB C: Placebo + ACEI/ ARB	24 weeks	BP, 24 h-proteinuria, estimated creatinine clearance, eGFR, potassium incidence of hyperkalemia
	Eschalier et al	2013	France	Parallel RCT	T: 1055 (746/ 309) C: 1072 (771/ 301)	T: EPL C: Placebo	42 months	eGFR, incidence of hyperkalemia
	Tylick et al	2012	Poland	Cross-over RCT	T: 18 C: 18	T: EPL + ARB C1: Aliskiren + ARB C2: ARB (double dose)	8 weeks	BP, UACR, eGFR, 24 h-proteinuria potassium
I	Lizakowski et al	2013	Poland	Cross-over RCT	T: 18 C: 18	T: EPL + ARB C1: Aliskiren + ARB C2: ARB (double dose)	8 weeks	BP, eGFR, potassium
	Kalizki et al	2016	Germany	Parallel RCT	T: 25 (19/6) C: 26 (22/4)	T: EPL + ACEI/ARB C: Placebo + ACEI/ ARB	26 weeks	BP, UACR

TABLE 1: The characteristics of the involved observational articles.

4

## International Journal of Hypertension

Endpoints	BP, UACR, incidence of hyperkalemia	BP, incidence of hyperkalemia	BP, the incidence of hyperkalemia	BP, UACR, creatinine	
Study duration	24 weeks	6 months	9 months	12 weeks	
Interventions	T: EPL C: Amlodipine	T: EPL C: ACEI	T: EPL C: ACEI	T: EPL C: Placebo	
No. of patients included (Male/Female)	T: 134 (61/73) C: 135 (66/69)	T: 253 (150/103) C: 246 (126/120)	T: 50 (31/19) C: 54 (30/24)	T: 35 (25/10) C: 22 (11/11)	
Study design	Parallel RCT	Parallel RCT	Parallel RCT	Parallel RCT	
Country	China	USA	NSA	Japan	
Year	2003	2004	2003	2016	
Author	White et al	Williams et al	Pitt et al	Eguchi et al	
No	16	17	18	19	

TABLE 1: Continued.

3.3.5. Effect of Treatment on Serum Creatinine. The effect of eplerenone treatment on serum creatinine was evaluated in 6 articles (n = 441). No significant heterogeneity was identified between the articles involved in the subgroups ( $Chi^2 = 2.90$ , P = 0.72,  $I^2 = 0\%$ ). And no significant changes were observed in the subgroups, eplerenone vs placebo (MD=-0.03, 95% CI = -0.16 to 0.10, P = 0.65), eplerenone vs thiazide diuretic (MD=0.06, 95% CI = -0.00 to 0.12, P = 0.07), and eplerenone vs RAS blockers (MD=0.02, 95% CI = -0.03 to 0.07, P = 0.45) (Figure 4(b)).

3.3.6. Effect of Treatment on Blood Pressure. The effect exerted by eplerenone treatment on blood pressure was evaluated in 16 articles (n = 1719) in total. In 7 articles comparing eplerenone to placebo, a significant change in SBP was reported in the eplerenone group (MD = -2.73, 95% CI = -4.86 to -0.59, P = 0.01), whereas in the subgroup of eplerenone vs thiazide diuretic, a significant change in SBP was reported in the control (MD = 3.98, 95% CI = 2.65-5.31, P < 0.00001), and no significant effect was identified compared with RAS blockers (MD = 0.53, 95% CI = -0.47 to 1.54, P = 0.30) and CCBs (MD = -0.40, 95% CI = -3.15 to 2.35, P = 0.78). In a pooled analysis of all articles, compared with placebo, the total effect slightly increased after eplerenone treatment (MD = 1.11, 95% CI = 0.39 to 1.83, P = 0.003). Furthermore, significant heterogeneity was found here among subgroups ( $Chi^2 = 40.71$ , P = 0.0004,  $I^2 = 63\%$ ) (Figure 5(a)).

However, in comparison with the control, the change of DBP (MD = 0.11, 95% CI = -0.41 to 0.63, P = 0.68) was not significantly different in the eplerenone treatment groups, and no heterogeneity was reported among subgroups (Chi<sup>2</sup> = 15.56, P = 0.41,  $I^2 = 4\%$ ). In articles comparing eplerenone vs placebo, DBP levels changed not significantly (MD = -0.58, 95% CI = -2.34 to 1.18, P = 0.52). Besides, the results in other articles were eplerenone vs thiazide diuretic (MD = -0.58, 95% CI = -1.84 to 0.67, P = 0.36), eplerenone vs RAS blockers (MD = 0.27, 95% CI = -0.35 to 0.89, P = 0.40), eplerenone vs CCBs (MD = 1.80, 95% CI = -0.80 to 4.40, P = 0.17) (Figure 5(b)), respectively.

3.3.7. Effect of Treatment on Serum Potassium Levels. There were 12 articles (n = 1032) showing a difference in potassium levels between the eplerenone treatment groups and the control (MD=-0.06, 95% CI = -0.08 to -0.03, P < 0.00001). Significant rises in potassium levels were reported in the subgroups of eplerenone vs placebo (MD = 0.13, 95% CI = 0.07 to 0.18, P < 0.00001) and eplerenone vs thiazide diuretic (MD = 0.18, 95% CI = 0.13 to 0.23, P < 0.00001), whereas a lower potassium level was identified in the subgroup of eplerenone vs RAS blockers (MD = -0.21, 95% CI = -0.24 to -0.18, P < 0.00001) (Figure 6).

#### 3.4. Adverse Events

3.4.1. Hyperkalemia ( $\geq$ 5.5 mmol/l). A total of 10 articles involving 4176 patients suggested a difference between the eplerenone treatment groups and the control group

regarding relative hyperkalemia risk (≥5.5 mmol/l). No significant difference was reported in the incidence of hyperkalemia in the subgroups of eplerenone vs thiazide diuretic (RR = 2.37, 95% CI = 0.37 to 15.16, P = 0.36), eplerenone vs RAS blockers (RR = 1.00, 95% CI = 0.07 to 15.12, P = 1.00) and eplerenone vs CCBs (RR = 2.01, 95%) CI = 0.38 to 10.82, P = 0.41), whereas in the subgroup of eplerenone vs placebo, a significant risk of hyperkalemia was reported in the eplerenone group (RR = 1.69, 95% CI = 1.34 to 2.13,  $P \le 0.00001$ ). Moreover, in a pooled analysis of all articles, the total risk of hyperkalemia ( $\geq$ 5.5 mmol/l) in the eplerenone group increased by approximately 70%  $(RR = 1.70, 95\% CI = 1.35 to 2.13, P \le 0.00001)$ , and no significant heterogeneity was identified in the subgroup trials involved here ( $Chi^2 = 1.90$ , P = 0.99,  $I^2 = 0\%$ ) (Figure 7(a)).

3.4.2. Hyperkalemia ( $\geq 6.0 \text{ mmol/l}$ ). Seven articles (n = 3394) indicated the difference in risk of hyperkalemia ( $\geq 6.0 \text{ mmol/l}$ ) l) between the eplerenone treatment groups and the control group (RR = 1.61, 95% CI = 1.06 to 2.44, P = 0.02). No significant change was identified in the subgroup of eplerenone vs placebo (RR = 1.30, 95% CI = 0.82 to 2.07, P = 0.26), whereas in the subgroup of eplerenone vs RAS blockers, a significant risk of hyperkalemia was reported in the eplerenone group (RR = 4.10, 95% CI = 1.40 to 11.99, P = 0.01), and the total heterogeneity was low (Chi<sup>2</sup> = 4.48, P = 0.35,  $I^2 = 11\%$ ) (Figure 7(b)).

3.5. Evaluation of Sensitivity Analysis and Publication Bias. Sensitivity analysis of the involved articles showed no literature caused significant interference with the results of the meta-analysis, which meant the involved articles had good stability. The funnel plots were systematically performed with the effectiveness and adverse events indicators, including 24-h proteinuria, UACR, systolic pressure, and eGFR. As indicated in Figure 8, the distribution of the (A) to (D) funnel plots was symmetrical, and the scatter points of the study were mostly within the scope of the funnel plots, thereby demonstrating that the possibility of publication bias was insignificant.

#### 4. Discussion

CKD results from diverse causes and is characterized by the progressive and irreversible loss of renal function, taking up about 11%–16% of the global population [25, 26]. Numerous basic and animal articles have verified that MRAs are capable of significantly suppressing the activity of proinflammatory cytokines and pro-oxidants, improving the anti-inflammatory response of kidney tissue, improving renal ischemia, mitigating collagen deposition, and preventing renal fibrosis [2, 27, 28]. Clinical articles also clearly indicate that MRAs are effective in treating chronic kidney disease. In this paper, we found that eplerenone has beneficial effects on CKD by reducing urinary protein and the systolic blood pressure, but with the risk of hyperkalemia at higher doses.

#### International Journal of Hypertension



FIGURE 2: (a) Risk of bias summary: review authors judgements about the respective risk of bias item for each involved study. (b) Risk of bias graph: review researchers' judgements about the respective risk of bias item presented as percentages across all involved articles.

Articles have suggested that renal proteinuria predicts the acceleration of the course of progressive renal insufficiency and the shorter survival period of CKD cases [29]. Accordingly, reducing proteinuria can benefit the kidneys and reduce the risk of progression to ESRD [30, 31]. As suggested by the existing research summary. Eplerenone alone or in combination with ACEI/ARB can further significantly reduce proteinuria in cases suffering CKD and increase creatinine clearance, independent of its antihypertensive effects [28]. In this meta-analysis, compared with the placebo control, eplerenone treatment improved the 24h urine protein and UACR levels of CKD cases, in line with the results of other existing articles [32]. However, this study revealed that no significant difference was reported in the efficacy of eplerenone treatment in comparison with the two controls of thiazide diuretic and RAS blockers in reducing urine protein. This finding is explained below. First, existing clinical trials and treatment experience have confirmed the major mechanism and beneficial effects of RAAS inhibitors to reduce urine protein for kidney protection. Second, no significant difference was reported between eplerenone and thiazide diuretics in reducing urine protein in this metaanalysis. Relevant literature articles suggested that thiazide drugs have a certain degree of urinary protein-lowering effect [33, 34], supporting the results of our study.

In this meta-analysis, the blood creatinine level of the eplerenone treatment group did not change significantly compared with the control group which is consistent with previous articles [35, 36]. However, articles have suggested that a small number of cases experienced deterioration in renal function after the addition of eplerenone treatment in CKD cases [37]. In comparison with the placebo group, the eGFR of the treatment group was reduced, and there were statistical differences, complying with the results of the above study. Considering that it is not correlated with the different baselines of the renal function of the subjects selected in the respective study, the renal function needs to be monitored in real time during the clinical application process. However, eGFR was more significantly reduced in the thiazide diuretic group, as compared with that of the eplerenone group. A prospective, multicentre clinical study (Cosmo-CKD) conducted in Japan demonstrated that, though hydrochlorothiazide can reduce urine protein and blood pressure [33], it reduces eGFR to a certain extent, complying with the results here. It is not considered to be correlated with increased aldosterone secondary to volume reduction [38].

In this meta-analysis, the effect of eplerenone on lowering SBP was better than that of the placebo group and weaker than that of the thiazide diuretic control and

Study on Subanous	e	plerenoi	ne	placebo	o/active	control	Weigh	t Mean Difference		Mean	n Diffe	rence	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, Fixed, 95% CI		IV, F	ixed, 95	5% CI	
1.1.1 eplerenone vs pl	acebo												
Boesby 2011	1,163	948	40	1,481	1,378.5	40	0.4	-318.00 [-836.46, 200.4	6] ←				
Boesby 2013	137	48.53	22	178	69.99	24	81.1	-41.00 [-75.57, -6.43]					
Subtotal (95% CI)			62			64	81.5	-42.23 [-76.72, -7.73]					
Heterogeneity: Chi <sup>2</sup> =	1.09, df	= 1 (P =	0.30);	$I^2 = 8\%$									
Test for overall effect:	Z = 2.40	P = 0.0	02)										
1.1.2 eplerenone vs th	iazide di	uretic											
Joffe 2007	154	128.89	8	163	65.19	8	9.7	-9.00 [-109.09, 91.09]		-	-	-	
Subtotal (95% CI)			8			8	9.7	-9.00 [-109.09, 91.09]	1	-	$\blacklozenge$		
Heterogeneity: Not ap	plicable												
Test for overall effect:	Z = 0.18	P = 0.8	86)										
1.1.3 eplerenone vs R.	AS block	ers											
Lizakowski 2013-1	2,180	763	18	1,980	703.7	18	0.4	200.00 [-279.50, 679.5	0]				
Lizakowski 2013-2	2,180	763	18	1,770	688.9	18	0.4	410.00 [-64.90, 884.90	)]				<b></b>
Tylick 2012-1	980	250	18	1,000	180	18	4.8	-20.00 [-162.31, 122.3]	1]		-	_	
Tylick 2012-2	980	250	18	970	280	18	3.2	10.00 [-163.41, 183.41	]				
Subtotal (95% CI)			72			72	8.9	22.24 [-82.35, 126.83]	1		$\blacklozenge$		
Heterogeneity: Chi <sup>2</sup> =	3.45, df	= 3 ( <i>P</i> =	0.33);	$I^2 = 13\%$									
Test for overall effect:	Z = 0.42	P = 0.0	58)										
Total (95% CI)			142			144	100.0	-33.30 [-64.43, -2.16]					
Heterogeneity: Chi <sup>2</sup> =	6.11, df	= 6 ( <i>P</i> =	0.41);	$I^2 = 2\%$						1		1	
Test for overall effect:	Z = 2.10	P = 0.0	04)						-500	-250	0	250	500
Test for subgroup diff	ferences:	$Chi^2 = 1$	1.57, df	= 2 ( <i>P</i> =	$0.46), I^2$	= 0%				eplerenone		placebo [active contro	ol]

(a) FIGURE 3: Continued.

Chulm an Cultana	e	plerenon	ie	placel	oo/active	control	Weigh	t Mean Difference	Mean I	Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, Fixed, 95% CI	IV, Fixe	d, 95% CI
1.7.1 eplerenone vs p	olacebo									
Ando 2014	-17.3	147.86	162	10.3	131.32	152	0.3	-27.60 [-58.49, 3.29]	_	4
Boesby 2011	-28.4	13.6905	40	-6.4	13.6905	40	8.5	-22.00 [-28.00, -16.00]		•
Eguchi 2016	-2.3	115.964	35	29.2	86.8431	22	0.1	-31.50 [-84.35, 21.35]	_	+
Jacobsen 2020	-35.5	84.07	70	17.5	83.33	70	0.4	-53.00 [-80.73, -25.27]	-	
Kalizki 2016	-3.3	174.309	25	10	0.0024	22	0.1	-13.30 [-81.63, 55.03]	_	+
Kovarik 2021	-75	600	7	47	51.33	8	0.0	-122.00 [-567.90, 323.90]	·	
Subtotal (95% CI)			339			314	9.4	-23.57 [-29.28, -17.86]		
Heterogeneity: Chi <sup>2</sup>	= 5.02,	df = 5 (P	= 0.41	); $I^2 = 0\%$	6					
Test for overall effec	t: $Z = 8$ .	09 ( $P < 0$	.00001	)						
1.7.2 eplerenone vs t	hiazide	diuretic								
Sawai 2017	92.445	3 120.8	98	176.987	584.2	97	0.0	-84.54 [-203.23, 34.15]		+
Subtotal (95% CI)			98			97	0.0	-84.54 [-203.23, 34.15]	-	
Heterogeneity: Not a	applicab	le								
Test for overall effec	t: $Z = 1.4$	40 (P = 0	.16)							
1.7.3 eplerenone vs l	RAS blo	ckers								
Epstein 2002	-62	267.609	74	-45	14.232	74	0.1	-17.00 [-78.06, 44.06]		+-
Mokadem 2020	91.04	37.32	24	100.3	44.38	23	0.6	-9.26 [-32.75, 14.23]		+
Tylick 2012-1	707	520	18	525	329.63	18	0.0	182.00 [-102.42, 466.42]		·
Tylick 2012-2	707	520	18	376	296.3	18	0.0	331.00 [54.52, 607.48]		
Subtotal (95% CI)			116			115	0.6	-9.12 [-30.98, 12.74]		
Heterogeneity: Chi <sup>2</sup>	= 1.80,	df = 2 (P	= 0.41	); $I^2 = 0\%$	6					
Test for overall effec	t: $Z = 0.$	82 ( $P = 0$	.41)							
1.7.4 eplerenone vs (	CCBs									
White 2003	-27.5	2.5962	134	-5	10.6362	135	89.9	-22.50 [-24.35, -20.65]		
Subtotal (95% CI)			134			135	89.9	-22.50 [-24.35, -20.65]		
Heterogeneity: Not a	applicab	le								
Test for overall effec	t: $Z = 23$	3.87 (P <	0.0000	1)						
Total (95% CI)			687			661	100.0	-22.53 [-24.28, -20.78]		
Heterogeneity: Chi <sup>2</sup>	= 9.44,	df = 10 (1)	P = 0.4	9); $I^2 = 0$	%					
Test for overall effec	t: $Z = 25$	5.21 (P <	0.0000	1)				r-	1	· · · · · · · · · · · · · · · · · · ·
Test for subgroup di	fference	s: Chi² =	2.62, 0	$\mathrm{lf}=3~(P$	= 0.45), I <sup>2</sup>	<sup>2</sup> = 0%		-50	0 -250 eplerenone	0 250 500 placebo [active control]
							(h)			
							(D)			

FIGURE 3: (a) Effect on 24-h proteinuria in articles comparing eplerenone to placebo/active control. (b) Effect on UACR for the eplerenone versus placebo/active control. The black diamond indicates summary information with the center of the estimate pooled with the median difference, and the width covers the relevant 95% CIs.

presented no significant difference in lowering blood pressure in comparison with the CCBs group. Additionally, no significant difference was reported between the changes in DBP and the controls. This result is inconsistent with the fact that eplerenone has a significant antihypertensive effect on SBD and DBP, as stated in some research results [32, 36]. The reasons for the difference between the results of this study and other articles are described as follows. (1) Thiazide diuretic suppresses the reabsorption of sodium chloride within the proximal and distal renal tubules, and it directly lowers blood pressure. Its antihypertensive effect may be stronger than the weaker diuretic effect of mineralocorticoid receptor antagonists, and this only targets the distal renal tubules and collecting ducts. (2) The comparison of the antihypertensive efficacy of eplerenone and CCBs is only involved in one study, with certain limitations. This can be clarified by further high-quality RCT articles. (3) In this meta-analysis, DBP was not significantly different from the control, and the changes were not excluded, which was

correlated with the good baseline blood pressure control of the respective involved study. In addition, there is no significant heterogeneity in a single subgroup in this metaanalysis, while the high total heterogeneity is considered to be correlated with the difference in antihypertensive effect attributed to different drug choices in the control.

For adverse drug reactions, researchers (e.g., Sawai et al. [14], Ando et al. [15], Williams et al. [22], and Pitt et al. [23]) elucidated the drug treatment-related side effects during the treatment and the follow-up, thereby demonstrating the occurrence of no significant severe adverse reactions. El Mokadem et al. [11] also revealed that it is not common to discontinue medication as impacted by side effects in the respective treatment group. In this meta-analysis, only statistical analysis of changes in serum potassium levels was performed, and the risk of hyperkalemia during Eplerenone treatment was discussed. Compared with the control, eplerenone increased serum potassium levels, which was statistically significant from the clinical perspective. The risk

Study or Subgroup	epi Mean	lerenone SD	e Total	placeb Mean	o/active c SD	ontrol Total	Weight (%)	Mean Difference IV, Fixed. 95% CI	Mean Difference IV, Fixed. 95% CI
1.2.1 oplanar 1	acaba	50	TOTAL	meall	50	TOTAL	(/0)	- , , r, <i>55</i> /0 GI	
1.2.1 epierenone vs pl	6/ 1	23 000	162	68	23 722	152	3.0	-3.90 [-0.00 1.20]	
Boesby 2011	81	∠3.099 35	40	08 86	23.732 35	40	0.3	-5.00 [-9.09, 1.29]	
Boesby 2013	50	19	22	54	28	24	0.4	-4.00 [-17.73, 9.73]	
Epstein 2006-1	72	15.037	91	72	15.037	91	4.3	0.00 [-4.37, 4.37]	·
Epstein 2006-2	66	20.815	86	72	15.037	91	2.8	-6.00 [-11.38, -0.62	1
Eschalier 2013	68.02	18.4	1336	69.11	18.2	1340	42.2	-1.09 [-2.48, 0.30]	
Jacobsen 2020	80.3	20.7	70	83.8	20.7	70	1.7	-3.50 [-10.36, 3.36]	I ————————————————————————————————————
Kovarik 2021 Subtotal (95% CI)	41.2	18.519	7 1814	61	44.889	8 1816	0.1 54.9	-19.80 [-53.80, 14.20 -1.56 [-2.78, -0.34]	] ←
Heterogeneity: Chi <sup>2</sup> Test for overall effec	= 6.06, t: $Z = 2$	df = 7 (F .51 (P =	P = 0.53 0.01)	b); $I^2 = 0\%$	)				
1.2.2 eplerenone vs th	iazide d	liuretic							
Joffe 2007	108	27	8	105	21	8	0.1	3.00 [-20.70, 26.70]	ı
Karashima 2016	72.7	3.2	25	65.6	3.1	25	26.6	7.10 [5.35, 8.85]	·   _
Sawai 2017	65.2	42	97	62.8	10.1	98	1.1	2.40 [-6.19, 10.99]	
Subtotal (95% CI)			130			131	27.9	6.89 [5.19, 8.60]	♦
Heterogeneity: Chi <sup>2</sup> Test for overall effec	= 1.21, t: Z = 7	df = 2 ( <i>I</i> .91 ( <i>P</i> <	P = 0.55 0.00001	5); $I^2 = 0\%$	ó				
1.2.3 eplerenone vs R.	AS bloc	kers							
Lizakowski 2013-1	90.7	7.1	18	90.4	7	18	3.8	0.30 [-4.31, 4.91]	+
Lizakowski 2013-2	90.7	7.1	18	89.7	7.1	18	3.8	1.00 [-3.64, 5.64]	- <del> </del>
Mokadem 2020	69.21	7.88	24	68.48	8.06	23	3.9	0.73 [-3.83, 5.29]	
Tylick 2012-1	97.3	8.1	18	96.9	8.3	18	2.8	0.40 [-4.96, 5.76]	+-
Tylick 2012-2	97.3	8.1	18	96.6	8.2	18	2.9	0.70 [-4.62, 6.02]	- <u>+</u>
			>						
Test for overall effec <i>Total (95% CI)</i> Heterogeneity: Chi <sup>2</sup>	t: $Z = 0$	.57 (P = 15)	(0.57) 2040 (P < 0)	00001): 1	<sup>2</sup> = 79%	2042	100.0	1.18 [0.27, 2.08]	· · · · · · · · · · · · · · · · · · ·
Test for overall effect Total (95% CI) Heterogeneity: Chi <sup>2</sup> Test for overall effect Test for subgroup d	et: $Z = 0$ = 70.07 et: $Z = 2$	.57 (P = 7, df = 15 .56 (P = es: Chi <sup>2</sup> :	0.57) 2040 6 (P < 0. 0.01) = 62.75	.00001); <i>I</i>	<sup>2</sup> = 79% P < 0.0000	2042 (01), $I^2 = 9$	<i>100.0</i> 96.8%	1.18 [0.27, 2.08]	-50 -25 0 25 placebo (active control) eplerenone
Test for overall effec <i>Total (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec Test for subgroup d	z: $Z = 0= 70.07z$ : $Z = 2ifference$	.57 (P = 7, df = 15 .56 (P = es: Chi <sup>2</sup> =	0.57) 2040 6 (P < 0. 0.01) = 62.75	00001); <i>I</i>	<sup>2</sup> = 79% P < 0.0000	2042 ()1), $I^2 = 9$	100.0 96.8% (a)	1.18 [0.27, 2.08]	-50 -25 0 25 placebo (active control) eplerenone
Test for overall effec <i>Total (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec Test for subgroup d Study or Subgroup	et: $Z = 0$ = 70.07 et: $Z = 2$ ifference epl Mean	f, df = 15 f, df = 15	$\begin{array}{c} 0.57 \\ 2040 \\ 5 (P < 0. \\ 0.01) \\ = 62.75 \\ \hline \\ $	.00001); <i>I</i> , df = 2 ( <i>I</i> placeb Mean	<sup>2</sup> = 79% P < 0.0000 o/active c	2042 (1), $I^2 = 9$ control Total	100.0 96.8% (a) Weight (%)	1.18 [0.27, 2.08] Mean Difference IV, Fixed, 95% CI	-50 -25 0 25 placebo (active control) eplerenone Mean Difference IV, Fixed, 95% CI
Test for overall effec <i>Total (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec Test for subgroup d Study or Subgroup	et: $Z = 0$ = 70.07 et: $Z = 2$ ifference epi Mean acebo	.57 ( <i>P</i> = <i>I</i> , <i>df</i> = 15 .56 ( <i>P</i> = es: Chi <sup>2</sup> : lerenone SD '	$\begin{array}{c} 0.57 \\ 2040 \\ 5 (P < 0. \\ 0.01) \\ = 62.75 \\ \hline \\ \end{array}$	00001); <i>I</i> , df = 2 ( <i>I</i> placeb Mean	<sup>2</sup> = 79% P < 0.0000 o/active c SD	$2042$ $(01), I^2 = 9$ $(01), I^2 = 9$ $(01), I^2 = 9$	100.0 96.8% (a) Weight (%)	1.18 [0.27, 2.08] Mean Difference IV, Fixed, 95% CI	-50 -25 0 25 placebo (active control) eplerenone Mean Difference IV, Fixed, 95% CI
Test for overall effec <i>Total (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec Test for subgroup d Study or Subgroup 1.9.1 eplerenone vs pl Decho 2011	tt: $Z = 0$ = 70.07 tt: $Z = 2$ ifference epi Mean acebo	.57 ( <i>P</i> = <i>f</i> , <i>df</i> = 15 .56 ( <i>P</i> = es: Chi <sup>2</sup> : lerenone SD	$\begin{array}{c} 0.57 \\ 2040 \\ 5 (P < 0. \\ 0.01) \\ = 62.75 \\ \hline \\ $	00001); <i>I</i> , df = 2 ( <i>I</i> placeb Mean	<sup>2</sup> = 79% P < 0.0000 o/active o SD	$2042$ $01), I^2 = 9$ ontrol Total	100.0 96.8% (a) Weight (%)	1.18 [0.27, 2.08] Mean Difference IV, Fixed, 95% CI	-50 -25 0 25 placebo (active control) eplerenone Mean Difference IV, Fixed, 95% CI
Test for overall effec <i>Total (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec Test for subgroup d Study or Subgroup 1.9.1 eplerenone vs pl Boesby 2011 Boesby 2012	tt: $Z = 0$ = 70.07 tt: $Z = 2$ ifference Mean acebo 1.56	.57 (P = 15, .56 (P = 15, .56 (P = es; Chi2)))	$\begin{array}{c} 0.57 \\ 2040 \\ 0.01 \\ 0.$	00001); <i>I</i> , df = 2 ( <i>I</i> placeb Mean	<sup>2</sup> = 79% P < 0.0000 o/active c SD 0.61	$2042$ $01), I^2 = 9$ ontrol Total $40$	100.0 96.8% (a) Weight (%)	1.18 [0.27, 2.08] Mean Difference IV, Fixed, 95% CI 0.05 [-0.22, 0.32]	-50 -25 0 25 placebo (active control) eplerenone Mean Difference IV, Fixed, 95% CI
Test for overall effec <i>Total (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec Test for subgroup d Study or Subgroup 1.9.1 eplerenone vs pl Boesby 2011 Boesby 2013	tt: $Z = 0$ = 70.07 tt: $Z = 2$ ifference Mean acebo 1.56 2.21	.57 (P = 15, .56 (P = 15), .56 (P = es; Chi2 = 15), .56 (P = es; Chi2 = 15), .56 (P = 15), .56	$\begin{array}{c} 0.57 \\ 2040 \\ (P < 0.001) \\ = 62.75 \\ \hline \\ \\ \hline \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ $	00001); <i>I</i> , df = 2 ( <i>I</i> placeb Mean 1.51 2.13	<sup>2</sup> = 79% P < 0.0000 o/active c SD 0.61 0.6	$2042$ $01), I^2 = 9$ $000000000000000000000000000000000000$	100.0 96.8% (a) Weight (%) 1.9 1.1	1.18 [0.27, 2.08] Mean Difference IV, Fixed, 95% CI 0.05 [-0.22, 0.32] 0.08 [-0.29, 0.45]	-50 -25 0 25 placebo (active control) eplerenone Mean Difference IV, Fixed, 95% CI
Test for overall effec <i>Total (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec Test for subgroup d Study or Subgroup 1.9.1 eplerenone vs pl Boesby 2011 Boesby 2013 Eguchi 2016 <i>Subtotal (95% CI)</i>	epi Mean acebo 1.56 2.21 0.8	57 (P = 15) 56 (P = 15) 56 (P = 15) 56 (P = 10) 60 = 100 100 = 1000 100 = 100 100 = 100 100 = 100 100 = 100 100 = 10	$\begin{array}{c} 0.57 \\ 2040 \\ 5 (P < 0. \\ 0.01) \\ = 62.75 \\ \hline \\ \\ \hline \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ $	00001); <i>I</i> , df = 2 ( <i>I</i> placeb Mean 1.51 2.13 0.88	<sup>2</sup> = 79% P < 0.0000 o/active c SD 0.61 0.6 0.36	2042 01), I <sup>2</sup> = 9 control Total 40 24 22 86	100.0 96.8% (a) Weight (%) 1.9 1.1 5.4 8.3	1.18 [0.27, 2.08] Mean Difference IV, Fixed, 95% CI 0.05 [-0.22, 0.32] 0.08 [-0.29, 0.45] -0.08 [-0.24, 0.08] -0.03 [-0.16, 0.10]	-50 -25 0 25 placebo (active control) eplerenone Mean Difference IV, Fixed, 95% CI
Test for overall effec <i>Total (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec Test for subgroup d Study or Subgroup 1.9.1 eplerenone vs pl Boesby 2011 Boesby 2013 Eguchi 2016 <i>Subtotal (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec	t: $Z = 0$ = 70.07 t: $Z = 2$ ifference Mean acebo 1.56 2.21 0.8 = 1.03, t: $Z = 0$	57 (P = 15, 56 (P = 15), 56 (	$\begin{array}{c} 0.57 \\ 2040 \\ (P < 0. \\ 0.01) \\ = 62.75 \\ \hline \\ Total \\ 40 \\ 22 \\ 35 \\ 97 \\ P = 0.60 \\ 0.65) \end{array}$	$00001); I$ $df = 2 (I$ $placeb$ Mean $1.51$ $2.13$ $0.88$ $0); I^{2} = 09$	<sup>2</sup> = 79% P < 0.0000 o/active o SD 0.61 0.6 0.36 6	2042 (1), $I^2 = 9$ control Total 40 24 22 86	100.0 96.8% (a) Weight (%) 1.9 1.1 5.4 8.3	1.18 [0.27, 2.08] Mean Difference IV, Fixed, 95% CI 0.05 [-0.22, 0.32] 0.08 [-0.29, 0.45] -0.08 [-0.24, 0.08] -0.03 [-0.16, 0.10]	-50 -25 0 25 placebo (active control) eplerenone Mean Difference IV, Fixed, 95% CI
Test for overall effec <i>Total (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec Test for subgroup d Study or Subgroup 1.9.1 eplerenone vs pl Boesby 2011 Boesby 2013 Eguchi 2016 <i>Subtotal (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec 1.9.2 eplerenone vs th	tt: $Z = 0$ = 70.07 tt: $Z = 2$ ifference epi Mean acebo 1.56 2.21 0.8 = 1.03, tt: $Z = 0$ iazide d	.57 (P =, .56 (P =, .56 (P =, .56 (P =, .57 (P =,	$\begin{array}{c} 0.57 \\ 2040 \\ 5 \ (P < 0. \\ 0.01) \\ = 62.75 \\ \hline \\ \hline \\ \hline \\ Total \\ 40 \\ 22 \\ 35 \\ 97 \\ P = 0.60 \\ 0.65 \\ \end{array}$	00001); I $df = 2 (I$ $df =$	<sup>2</sup> = 79% <sup>p</sup> < 0.0000 0/active c SD 0.61 0.6 0.36 6	2042 (1), $I^2 = 9$ control Total 40 24 22 86	100.0 96.8% (a) Weight (%) 1.9 1.1 5.4 8.3	1.18 [0.27, 2.08] Mean Difference IV, Fixed, 95% CI 0.05 [-0.22, 0.32] 0.08 [-0.29, 0.45] -0.08 [-0.24, 0.08] -0.03 [-0.16, 0.10]	-50 -25 0 25 placebo (active control) eplerenone Mean Difference IV, Fixed, 95% CI
Test for overall effec <i>Total (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec Test for subgroup d Study or Subgroup 1.9.1 eplerenone vs pl Boesby 2011 Boesby 2013 Eguchi 2016 <i>Subtotal (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec 1.9.2 eplerenone vs th Loffe 2007	tt: $Z = 0$ = 70.07 tt: $Z = 2$ ifference epi Mean acebo 1.56 2.21 0.8 = 1.03, tt: $Z = 0$ iazide d	57 (P = 15, 56 (P = 15, 56 (P = 15), 56 (P	0.57) 2040 ((P < 0. 0.01) = 62.75 Total 40 22 35 97 P = 0.60 0.65)	00001); I $df = 2 (I$ placeb Mean $1.51$ 2.13 0.88 0); I <sup>2</sup> = 09	<sup>2</sup> = 79% <sup>p</sup> < 0.0000 o/active o SD 0.61 0.6 0.36 6 0.2	2042 01), I <sup>2</sup> = 9 control Total 40 24 22 86	100.0 96.8% (a) Weight (%) 1.9 1.1 5.4 8.3 2.3	1.18 [0.27, 2.08] Mean Difference IV, Fixed, 95% CI 0.05 [-0.22, 0.32] 0.08 [-0.29, 0.45] -0.08 [-0.24, 0.08] -0.03 [-0.16, 0.10]	-50 -25 0 25 placebo (active control) eplerenone
Test for overall effec <i>Total (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec Test for subgroup d Study or Subgroup 1.9.1 eplerenone vs pl Boesby 2011 Boesby 2013 Eguchi 2016 <i>Subtotal (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec 1.9.2 eplerenone vs th Joffe 2007 Sawai 2017	tt: $Z = 0$ = 70.07 tt: $Z = 2$ ifference Mean acebo 1.56 2.21 0.8 = 1.03, tt: $Z = 0$ iazide d 1.1 0.82	57 (P = 15, 56 (P = 15, 56 (P = 15), 56 (P	$\begin{array}{c} 2040\\ (P < 0.001)\\ = 62.75\\ \hline \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$	00001); <i>I</i> , df = 2 ( <i>I</i> placeb Mean 1.51 2.13 0.88 0); $I^2 = 0$ 9 1.1 0.76	P < 0.0000 o/active o SD 0.61 0.6 0.36 6 0.2 0.21	2042 (1), $I^2 = 9$ control Total 40 24 22 86 8 97	100.0 96.8% (a) Weight (%) 1.9 1.1 5.4 8.3 2.3 35.7	1.18 [0.27, 2.08] Mean Difference IV, Fixed, 95% CI 0.05 [-0.22, 0.32] 0.08 [-0.29, 0.45] -0.08 [-0.24, 0.08] -0.03 [-0.16, 0.10] 0.00 [-0.25, 0.25] 0.06 [-0.00 0.12]	-50 -25 0 25 placebo (active control) eplerenone
Test for overall effec <i>Total (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec Test for subgroup d Study or Subgroup 1.9.1 eplerenone vs pl Boesby 2011 Boesby 2013 Eguchi 2016 <i>Subtotal (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec 1.9.2 eplerenone vs th Joffe 2007 Sawai 2017 Subtotal (95% CI) Heterogeneity: Chi <sup>2</sup>	epi Mean acebo 1.56 2.21 0.8 = 1.03, ct: Z = 0 iazide d 1.1 0.82 = 0.21	57 (P = 57) f, df = 15 56 (P = 50) es: Chi <sup>2</sup> = 50 (P = 50) (0.64) 0.64 0.67 0.19 df = 2 ( <i>I</i> 0.45 (P = 50) liuretic 0.3 0.24 df = 1 ( <i>I</i> )	$\begin{array}{c} 2040\\ (P < 0. \\ 0.01)\\ = 62.75\\ \hline \\ Total\\ 40\\ 22\\ 35\\ 97\\ P = 0.60\\ 0.65)\\ \hline \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$	00001); I $df = 2 (I$ placeb Mean $1.51$ $2.13$ $0.88$ $0); I^{2} = 09$ $1.1$ $0.76$ $b); I^{2} = 09$	$2^{2} = 79\%$ P < 0.0000 0/active c SD 0.61 0.66 0.36 6 0.2 0.21 6	2042 01), $I^2 = 9$ control Total 40 24 22 86 8 97 105	100.0 96.8% (a) Weight (%) 1.9 1.1 5.4 8.3 2.3 35.7 38.0	1.18 [0.27, 2.08] Mean Difference IV, Fixed, 95% CI 0.05 [-0.22, 0.32] 0.08 [-0.29, 0.45] -0.08 [-0.24, 0.08] -0.03 [-0.16, 0.10] 0.00 [-0.25, 0.25] 0.06 [-0.00, 0.12] 0.06 [-0.00, 0.12]	-50 -25 0 25 placebo (active control) eplerenone
Test for overall effec <i>Total (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec Test for subgroup d Study or Subgroup 1.9.1 eplerenone vs pl Boesby 2011 Boesby 2013 Eguchi 2016 <i>Subtotal (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec Subtotal (95% CI) Heterogeneity: Chi <sup>2</sup> Subtotal (95% CI) Heterogeneity: Chi <sup>2</sup> Test for overall effec	tt: $Z = 0$ = 70.07 tt: $Z = 2$ ifference mean acebo 1.56 2.21 0.8 = 1.03, tt: $Z = 0$ iazide d 1.1 0.82 = 0.21, tt: $Z = 1$	57 (P = 57) (P = 57	$\begin{array}{c} 2040\\ (P < 0. \\ 0.01)\\ = 62.75\\ \hline \\ Total\\ \hline \\ 40\\ 22\\ 35\\ 97\\ P = 0.66\\ 0.65)\\ \hline \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$	$00001); I$ $df = 2 (I$ placeb Mean $1.51$ 2.13 0.88 $0); I^{2} = 09$ $1.1$ 0.76 $5); I^{2} = 09$	<sup>2</sup> = 79% P < 0.0000 o/active o SD 0.61 0.6 0.36 6 0.2 0.21 6	2042 01), $I^2 = 9$ ontrol Total 40 24 22 86 8 97 105	100.0 96.8% (a) Weight (%) 1.9 1.1 5.4 8.3 2.3 35.7 38.0	1.18 [0.27, 2.08] Mean Difference IV, Fixed, 95% CI 0.05 [-0.22, 0.32] 0.08 [-0.29, 0.45] -0.08 [-0.24, 0.08] -0.03 [-0.16, 0.10] 0.00 [-0.25, 0.25] 0.06 [-0.00, 0.12] 0.06 [-0.00, 0.12]	-50 -25 0 25 placebo (active control) eplerenone
Test for overall effec <i>Total (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec Test for subgroup d Study or Subgroup 1.9.1 eplerenone vs pl Boesby 2011 Boesby 2013 Eguchi 2016 <i>Subtotal (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec 1.9.2 eplerenone vs th Joffe 2007 Sawai 2017 <i>Subtotal (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec 1.9.3 eplerenone vs R.	et: $Z = 0$ = 70.07 t: $Z = 2$ ifference mean acebo 1.56 2.21 0.8 = 1.03, ct: $Z = 0$ iazide d 1.1 0.82 = 0.21, ct: $Z = 1$ AS block	57 (P = 57) (P = 57	$\begin{array}{c} 0.57)\\ 2040\\ ((P < 0.00)\\ = 62.75\\ \hline \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$	00001); I $df = 2 (I$ placeb Mean $1.51$ $2.13$ $0.88$ $0); I^{2} = 09$ $1.1$ $0.76$ $5); I^{2} = 09$	P < 0.0000 P < 0.0000 $0.4 \text{ cm}^2$ 0.61 0.6 0.36 0.36 0.2 0.21 6	2042 (1), $I^2 = 9$ control Total 40 24 22 86 8 97 105	100.0 96.8% (a) Weight (%) 1.9 1.1 5.4 8.3 2.3 35.7 38.0	1.18 [0.27, 2.08] Mean Difference IV, Fixed, 95% CI 0.05 [-0.22, 0.32] 0.08 [-0.29, 0.45] -0.08 [-0.24, 0.08] -0.03 [-0.16, 0.10] 0.00 [-0.25, 0.25] 0.06 [-0.00, 0.12] 0.06 [-0.00, 0.12]	-50 -25 0 25 placebo (active control) eplerenone
Test for overall effec <i>Total (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec Test for subgroup d Study or Subgroup 1.9.1 eplerenone vs pl Boesby 2011 Boesby 2013 Eguchi 2016 <i>Subtotal (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec 1.9.2 eplerenone vs th Joffe 2007 Sawai 2017 Subtotal (95% CI) Heterogeneity: Chi <sup>2</sup> Test for overall effec 1.9.3 eplerenone vs R. Mokadem 2020 Subtotal (95% CI)	tt: $Z = 0$ = 70.07 tt: $Z = 2$ ifference mean acebo 1.56 2.21 0.8 = 1.03, tt: $Z = 0$ iazide d 1.1 0.82 = 0.21, tt: $Z = 1$ AS bloct 1.12	57 (P = 57) (P = 57	$\begin{array}{c} 0.57)\\ 2040\\ (P < 0.\\ 0.01)\\ = 62.75\\ \hline\\ Total\\ 40\\ 22\\ 35\\ 97\\ P = 0.66\\ 0.65)\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ $	00001); I $df = 2 (I$ placeb Mean $1.51$ 2.13 $0.88$ $0); I^{2} = 09$ $1.1$ $0.76$ $5); I^{2} = 09$ $1.1$	<pre><sup>2</sup> = 79% P &lt; 0.0000 o/active o SD 0.61 0.6 0.36 6 0.2 0.21 6 0.08</pre>	$2042$ 01), $I^{2} = 9$ ontrol Total 40 24 22 86 8 97 105 23 23 23	100.0 96.8% (a) Weight (%) 1.9 1.1 5.4 8.3 2.3 35.7 38.0 53.6 53.6 53.6	1.18 [0.27, 2.08] Mean Difference IV, Fixed, 95% CI 0.05 [-0.22, 0.32] 0.08 [-0.29, 0.45] -0.08 [-0.29, 0.45] -0.03 [-0.16, 0.10] 0.00 [-0.25, 0.25] 0.06 [-0.00, 0.12] 0.06 [-0.00, 0.12] 0.02 [-0.03, 0.07] 0.02 [-0.03, 0.07]	-50 -25 0 25 placebo (active control) eplerenone
Test for overall effec <i>Total (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec Test for subgroup d Study or Subgroup 1.9.1 eplerenone vs pl Boesby 2011 Boesby 2013 Eguchi 2016 <i>Subtotal (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec 1.9.2 eplerenone vs th Joffe 2007 Sawai 2017 Subtotal (95% CI) Heterogeneity: Chi <sup>2</sup> Test for overall effec 1.9.3 eplerenone vs R. Mokadem 2020 Subtotal (95% CI) Heterogeneity: Not Test for overall effec	tt: $Z = 0$ = 70.07 tt: $Z = 2$ ifference mean acebo 1.56 2.21 0.8 = 1.03, tt: $Z = 0$ iazide d 1.1 0.82 = 0.21, tt: $Z = 1$ AS bloct 1.12 applical tt: $Z = 0$	57 (P = 57) (P = 57	$\begin{array}{c} 0.57)\\ 2040\\ ((P < 0.001)\\ = 62.75\\ \hline\\ Total\\ \hline\\ 40\\ 22\\ 35\\ 97\\ P = 0.66\\ 0.65)\\ \hline\\ 8\\ 98\\ 106\\ P = 0.65\\ 0.07)\\ \hline\\ 24\\ 24\\ 0.45)\\ \end{array}$	$00001); I$ $f = 2 (I$ placeb Mean $1.51$ 2.13 0.88 $0); I^{2} = 09$ $1.1$ 0.76 $5); I^{2} = 09$ $1.1$	$2^{2} = 79\%$ P < 0.0000 o/active c SD 0.61 0.6 0.36 6 0.2 0.21 6 0.08	$2042$ (01), $I^2 = 9$ (0) (0) (1) (1) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2	100.0 96.8% (a) Weight (%) 1.9 1.1 5.4 8.3 2.3 35.7 38.0 53.6 53.6 53.6	1.18 [0.27, 2.08] Mean Difference IV, Fixed, 95% CI 0.05 [-0.22, 0.32] 0.08 [-0.29, 0.45] -0.08 [-0.24, 0.08] -0.03 [-0.16, 0.10] 0.00 [-0.25, 0.25] 0.06 [-0.00, 0.12] 0.06 [-0.00, 0.12] 0.02 [-0.03, 0.07] 0.02 [-0.03, 0.07]	-50 -25 0 25 placebo (active control) eplerenone
Test for overall effec <i>Total (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec Test for subgroup d Study or Subgroup 1.9.1 eplerenone vs pl Boesby 2013 Eguchi 2016 <i>Subtotal (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec 1.9.2 eplerenone vs th Joffe 2007 Sawai 2017 <i>Subtotal (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec 1.9.3 eplerenone vs R. Mokadem 2020 <i>Subtotal (95% CI)</i> Heterogeneity: Not Test for overall effec <i>Subtotal (95% CI)</i> Heterogeneity: Not Test for overall effec <i>Total (95% CI)</i>	t: $Z = 0$ = 70.07 t: $Z = 2$ ifference Mean acebo 1.56 2.21 0.8 = 1.03, ct: $Z = 0$ iazide d 1.1 0.82 = 0.21, ct: $Z = 1$ AS bloc: 1.12 applical ct: $Z = 0$	57 (P = 57) (P = 57	$\begin{array}{c} 0.57)\\ 2040\\ (P < 0.00)\\ = 62.75\\ \hline\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ $	00001); I $df = 2 (I$ placeb Mean $1.51$ 2.13 0.88 0); I <sup>2</sup> = 09 $1.1$ 0.76 5); I <sup>2</sup> = 09 $1.1$	<sup>2</sup> = 79% P < 0.0000 o/active of SD 0.61 0.6 0.61 0.6 0.36 6 0.21 6 0.08	$2042$ (01), $I^2 = 9$ (0) (0) (1) (1) (1) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2	100.0 96.8% (a) Weight (%) 1.9 1.1 5.4 8.3 2.3 35.7 38.0 53.6 53.6 53.6 100.0	1.18 [0.27, 2.08] Mean Difference IV, Fixed, 95% CI 0.05 [-0.22, 0.32] 0.08 [-0.29, 0.45] -0.08 [-0.24, 0.08] -0.03 [-0.16, 0.10] 0.00 [-0.25, 0.25] 0.06 [-0.00, 0.12] 0.06 [-0.00, 0.12] 0.06 [-0.00, 0.12] 0.02 [-0.03, 0.07] 0.02 [-0.03, 0.07]	-50 -25 0 25 placebo (active control) eplerenone
Test for overall effec <i>Total (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec Test for subgroup d Study or Subgroup 1.9.1 eplerenone vs pl Boesby 2011 Boesby 2013 Eguchi 2016 Subtotal (95% CI) Heterogeneity: Chi <sup>2</sup> Test for overall effec 1.9.2 eplerenone vs th Joffe 2007 Sawai 2017 Subtotal (95% CI) Heterogeneity: Chi <sup>2</sup> Test for overall effec 1.9.3 eplerenone vs R. Mokadem 2020 Subtotal (95% CI) Heterogeneity: Not Test for overall effec <i>Total (95% CI)</i> Heterogeneity: Chi <sup>2</sup>	tt: $Z = 0$ = 70.07 tt: $Z = 2$ ifference Mean acebo 1.56 2.21 0.8 = 1.03, tt: $Z = 0$ iazide d 1.1 0.82 = 0.21, tt: $Z = 1$ AS bloct 1.12 applical tt: $Z = 0$ = 2.90,	57 (P = 57) (P = 57	$\begin{array}{c} 0.57)\\ 2040\\ (P < 0.001)\\ = 62.75\\ \hline\\ Total\\ 40\\ 22\\ 35\\ 97\\ P = 0.66\\ 0.65)\\ \\ 8\\ 98\\ 106\\ P = 0.65\\ 0.07)\\ \\ 24\\ 24\\ 0.45)\\ \\ 227\\ P = 0.72\\ \hline\\ 227\\ P = 0.72\\ \hline\\ 24\\ 24\\ P = 0.72\\ \hline\\ 24\\ 24\\ P = 0.72\\ \hline\\ 227\\ P = 0.72\\ \hline\\ 227\\ P = 0.72\\ \hline\\ 24\\ 24\\ P = 0.72\\ \hline\\ 24\\ 24\\ P = 0.72\\ \hline\\ 227\\ P = 0.72\\ \hline\\ 24\\ 24\\ P = 0.72\\ \hline\\ 25\\ 27\\ P = 0.72\\ \hline\\ 25\\ 27\\ P = 0.72\\ \hline\\ 25\\ 27\\ 27\\ P = 0.72\\ \hline\\ 24\\ 24\\ 24\\ P = 0.72\\ \hline\\ 24\\ 24\\ 24\\ 24\\ 24\\ 24\\ 24\\ 24\\ 24\\ 24$	00001); I $df = 2 (I$ placeb Mean $1.51$ $2.13$ $0.88$ $0); I^{2} = 09$ $1.1$ $0.76$ $5); I^{2} = 09$ $1.1$	<sup>2</sup> = 79% P < 0.0000 o/active of SD 0.61 0.6 0.36 6 0.2 0.21 6 0.08	2042 01), I <sup>2</sup> = 9 control Total 40 24 22 86 8 97 105 23 23 23 214	100.0 96.8% (a) Weight (%) 1.9 1.1 5.4 8.3 2.3 35.7 38.0 53.6 53.6 53.6 100.0	1.18 [0.27, 2.08] Mean Difference IV, Fixed, 95% CI 0.05 [-0.22, 0.32] 0.08 [-0.29, 0.45] -0.08 [-0.24, 0.08] -0.03 [-0.16, 0.10] 0.00 [-0.25, 0.25] 0.06 [-0.00, 0.12] 0.06 [-0.00, 0.12] 0.06 [-0.00, 0.12] 0.02 [-0.03, 0.07] 0.02 [-0.03, 0.07]	-50 -25 0 25 placebo (active control) eplerenone
Test for overall effec <i>Total (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec Test for subgroup d Study or Subgroup 1.9.1 eplerenone vs pl Boesby 2011 Boesby 2013 Eguchi 2016 <i>Subtotal (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec 1.9.2 eplerenone vs th Joffe 2007 Sawai 2017 Subtotal (95% CI) Heterogeneity: Chi <sup>2</sup> Test for overall effec 1.9.3 eplerenone vs R. Mokadem 2020 Subtotal (95% CI) Heterogeneity: Not Test for overall effec <i>Total (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec <i>Total (95% CI)</i> Heterogeneity: Chi <sup>2</sup> Test for overall effec	tt: $Z = 0$ = 70.07 tt: $Z = 2$ ifference mean acebo 1.56 2.21 0.8 = 1.03, tt: $Z = 0$ iazide d 1.1 0.82 = 0.21, tt: $Z = 1$ AS blocc 1.12 applical tt: $Z = 0$ = 2.90, tt: $Z = 1$	57 (P = 57) (P = 57	$\begin{array}{c} 0.57)\\ 2040\\ ((P < 0.001)\\ = 62.75\\ \hline\\ Total\\ 40\\ 22\\ 35\\ 97\\ P = 0.60\\ 0.65)\\ \\ 8\\ 98\\ 106\\ P = 0.65\\ 0.07)\\ \\ 24\\ 24\\ 0.45)\\ \\ 227\\ P = 0.72\\ 0.12)\\ \end{array}$	00001); I $df = 2 (I$ placeb Mean $1.51$ 2.13 0.88 $0); I^{2} = 09$ $1.1$ 0.76 $5); I^{2} = 09$ $1.1$	$2^{2} = 79\%$ P < 0.0000 $0.4 \text{ cm}^{2} = 79\%$ $0.6 \text{ cm}^{2}$ 0.61 0.6 0.36 0.2 0.21 6 0.08	2042 01), I <sup>2</sup> = 9 control Total 40 24 22 86 8 97 105 23 23 214	100.0 96.8% (a) Weight (%) 1.9 1.1 5.4 8.3 2.3 35.7 38.0 53.6 53.6 53.6 53.6 100.0	1.18 [0.27, 2.08] Mean Difference IV, Fixed, 95% CI 0.05 [-0.22, 0.32] 0.08 [-0.29, 0.45] -0.08 [-0.29, 0.45] -0.08 [-0.24, 0.08] -0.03 [-0.16, 0.10] 0.00 [-0.25, 0.25] 0.06 [-0.00, 0.12] 0.06 [-0.00, 0.12] 0.02 [-0.03, 0.07] 0.02 [-0.03, 0.07]	-50 -25 0 25 placebo (active control) eplerenone



FIGURE 4: (a) Effect on eGFR in articles comparing eplerenone to placebo/active control. (b) Effect on serum creatinine for the eplerenone versus placebo/active control. The black diamond indicates summary information with the center of the estimate pooled with the median difference, and the width covers the relevant 95% CIs.

			plac	ebo/ac	tive							
Study on Sub moun	eplereno	one	C	control	l	Weight	Mean Difference		Mear	n Differen	ce	
Study or Subgroup	Mean SD	Total	Mean	SD	Total	(%)	IV, Fixed, 95% CI		IV, Fi	xed, 95% (	CI	
1.3.1 eplerenone vs	olacebo											
Ando 2014	128.8 14.059	9 162	132.2	14.917	7 152	5.1	-3.40 [-6.61, -0.19]		_	-		
Boesby 2011	121 11	40	124	11	40	2.3	-3.00 [-7.82, 1.82]			-		
Boesby 2013	125 14	22	131	16	24	0.7	-6.00 [-14.67, 2.67]					
Eguchi 2016	145 17	35	146	9	22	1.1	-1.00 [-7.77, 5.77]					
Jacobsen 2020	126 23.48	70	124	17.07	70	1.1	2.00 [-4.80, 8.80]		-		_	
Kalizki 2016	131 12	25	136	14	26	1.0	-5.00 [-12.15, 2.15]					
Kovarik 2021	151 9.4815	5 7	144.5	25.63	8	0.1	6.50 [-12.60, 25.60]					
Subtotal (95% CI)		361			342	11.5	-2.73 [-4.86, -0.59]		•			
Heterogeneity: Chi2	= 4.12, df = 6	(P = 0.66); I	$^{2} = 0\%$									
Test for overall effec	t: $Z = 2.50 (P$	= 0.01)										
1.3.2 eplerenone vs t	hiazide diure	tic										
Ioffe 2007	128 15	8	125	16	8	0.2	3.00 [-12.20, 18.20]					_
Karashima 2016	127 3	25	123	2	25	26.2	4.00 [2.59, 5.41]					
Sawai 2017	134.8 15.2	98	130.9	14.4	97	3.0	3.90 [-0.26, 8.06]				-	
Subtotal (95% CI)		131			130	29.5	3.98 [2.65, 5.31]			•		
Heterogeneity: Chi <sup>2</sup>	= 0.02, df = 2	(P = 0.99); I	$^{2} = 0\%$									
Test for overall effec	t: Z = 5.86 (P	< 0.00001)										
1.3.3 eplerenone vs ]	RAS blockers											
Mokadem 2020	127.08 4.4	24	126.3	4.05	23	9.0	0.78 [-1.64, 3.20]			<b>_</b>		
Pitt 2003	135.8 11.9	50	136.9	12.3	54	2.4	-1.10 [-5.75, 3.55]		_			
Tvlick 2012-1	121.5 2.6	18	120.6	2.4	18	19.6	0.90 [-0.73, 2.53]					
Tylick 2012-2	121.5 2.6	18	120.5	2.8	18	16.8	1.00 [-0.77, 2.77]					
Williams 2004	140.7 14	135	143.2	14.6	128	4.4	-2.50 [-5.96, 0.96]					
Subtotal (95% CI)		245			241	52.1	0.53 [-0.47, 1.54]			•		
Heterogeneity: Chi <sup>2</sup>	= 3.93, df = 4	(P = 0.42); I	$^{2} = 0\%$							ľ		
Test for overall effec	t: $Z = 1.04 (P$	= 0.30)										
1.3.4 eplerenone vs	CCBs											
White 2003	145.5 11	134	145.9	12	135	6.9	-0.40 [-3.15, 2.35]			_		
Subtotal (95% CI)		134			135	6.9	-0.40 [-3.15, 2.35]			•		
Heterogeneity: Not	applicable									Ť		
Test for overall effec	t: $Z = 0.29 (P$	= 0.78)										
Total (95% CI)		871			848	100.0	1.11 [0.39, 1.83]			•		
Heterogeneity: Chi <sup>2</sup>	= 40.71. df =	15(P = 0.000)	$(04); I^2 =$	63%			[,]		1			
Test for overall effec	t: $Z = 3.01 (P)$	= 0.003)	. ,,=					-20	-10	0	10	20
Test for subgroup di	fferences: Chi	$^{2} = 32.65, df$	= 3 (P <	0.000	01), <i>I</i> <sup>2</sup>	= 90.8%		eple	erenone	placebo	(active	control)
- 1												

(a) FIGURE 5: Continued.

				plac	ebo/ac	tive				
	er	lereno	ne	-	control		Weight	Mean Difference	Mean	Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, Fixed, 95% CI	IV, Fix	ed, 95% CI
1.4.1 eplerenone vs p	lacebo									
Ando 2014	76.7	11.798	162	78.4	12.476	5 152	3.7	-1.70 [-4.39, 0.99]		
Boesby 2011	83	10	40	85	10	40	1.4	-2.00 [-6.38, 2.38]		
Boesby 2013	77	9	22	81	12	24	0.7	-4.00 [-10.10, 2.10]	<u> </u>	
Eguchi 2016	80	10	35	75	11	22	0.8	5.00 [-0.67, 10.67]		
Jacobsen 2020	78	14.94	70	78	17.07	70	1.0	0.00 [-5.31, 5.31]		
Kalizki 2016	87	10	25	85	9	22	0.9	2.00 [-3.43, 7.43]	-	
Kovarik 2021	87.5	16.37	7	81	8.7407	7 8	0.1	6.50 [-7.06, 20.06]		
Subtotal (95% CI)			361			338	8.7	-0.58 [-2.34, 1.18]		♦
Heterogeneity: Chi <sup>2</sup>	= 7.96,	df = 6	(P = 0.24);	$I^2 = 25\%$	,					
Test for overall effec	t: $Z = 0$	.65 (P =	= 0.52)							
1.4.2 eplerenone vs t	hiazide	e diuret	ic							
Ioffe 2007	72	11	8	71	8	8	0.3	1.00 [-8.43, 10.43]		
Karashima 2016	71	3	25	72	2	25	13.5	-1.00 [-2.41, 0.41]		
Sawai 2017	75.3	10.3	98	74.3	10.2	97	3.3	1.00 [-1.88, 3.88]		_ <b>_</b>
Subtotal (95% CI)			131			130	17.1	-0.58 [-1.84, 0.67]		•
Heterogeneity: Chi <sup>2</sup>	= 1.61,	df = 2	(P = 0.45);	$I^2 = 0\%$						
Test for overall effect	t: $Z = 0$	.91 (P =	= 0.36)							
1 4 2	AC 1.1.	1								
1.4.5 epierenone vs I	CAS DIC	ockers	24	70 70	2.10	22		1.26 [ 0.04 2.46]		
Mokadem 2020	81.04	4.42	24	/9./8	3.19	23	5.6	1.26 [-0.94, 3.46]		
Pitt 2003	84.3	5.9	50	84	/.1	54	4.3	0.30 [-2.20, 2.80]		- <b>-</b>
Tylick 2012-1	76.6	1.9	18	/5.8	2	18	10.0	0.80[-0.47, 2.07]		<b>1</b> ∎−
Tylick 2012-2	/4.0	1.9	18	/4.4	2.2	18	14.9	0.20 [-1.14, 1.54]		T
Subtotal (95% CI)	85.0	4.1	245	65.6	5.9	2/1	20.0 70.3	-0.20 [-1.17, 0.77]		T
Hataraganaitu: Chi <sup>2</sup>	- 2 26	df = 4	(D = 0.67).	$1^2 - 00^4$		271	70.5	0.27 [-0.33, 0.07]		Y
Test for overall effect	= 2.30, t. 7 - 0	$a_1 = 4$ 85 (D -	(P = 0.67); = 0.40)	$I^{-} = 0\%$						
lest for overall effec	ι. <u>Σ</u> = 0	.05 (F -	- 0.40)							
1.4.4 eplerenone vs (	CCBs									
White 2003	74.9	10	134	73.1	11.7	135	4.0	1.80 [-0.80, 4.40]		<b>+-</b>
Subtotal (95% CI)			134			135	4.0	1.80 [-0.80, 4.40]		•
Heterogeneity: Not a	pplical	ble								
Test for overall effect	t: $Z = 1$	.36 (P =	= 0.17)							
Total (95% CI)			871			844	100.0	0.11 [-0.41, 0.63]		•
Heterogeneity: Chi <sup>2</sup>	= 15.56	5, df = 1	5(P=0.4)	1); $I^2 = 49$	%					
Test for overall effec	t: $Z = 0$	.42 (P =	= 0.68)					-20	-10	0 10 20
Test for subgroup di	fference	es: Chi <sup>2</sup>	$^{2} = 3.63$ , df	= 3 (P =	0.30),	$I^2 = 17$	.4%		eplerenone	placebo (active control)

(b)

FIGURE 5: Forest plots of the effects on blood pressure between the eplerenone treatment groups and the control group. (a) Effect on SBP in articles comparing eplerenone to placebo/active control. (b) Effect on DBP in articles comparing eplerenone to placebo/active control. The black diamond indicates summary information with the center of the estimate pooled with the median difference, and the width covers the relevant 95% CIs.

of hyperkalemia fell to two levels of  $\geq$ 5.5 mmol/l and  $\geq$ 6.0 mmol/l for statistics. In the hyperkalemia risk ( $\geq$ 5.5 mmol/l) group, in comparison with the placebo, eplerenone treatment was accompanied by hyperkalemia risk. No significant difference was reported in other subgroups, complying with the results of some articles [32, 36, 37], demonstrating that MRAs may be associated with the risk of hyperkalemia. There are also articles verifying that there is no significant risk of high potassium in eplerenone treatment [39]. The reasons for the differences in the research results are analysed as follows. From one perspective, it is considered to be correlated with the increased risk of high potassium with the combined application of ACEI/ARB drugs in the involved articles. Moreover, the differences in the baseline blood potassium

levels and baseline renal function of the populations involved in different articles are not excluded, and the risk of hyperkalemia is significantly increased in cases suffering high baseline blood potassium levels and poor renal function [40]. From another perspective, some articles have different definitions of the threshold of hyperkalemia risk (some are defined as  $\geq$ 5.5 mmol/l, and some articles are defined as 6.0 mmol/l). However, eplerenone treatment is associated with the risk of hyperkalemia compared with the RAS blockers control. This is considered to be associated with the high-dose eplerenone treatment (100–200 mg) in the two selected articles in this treatment subgroup.

Lastly, this research has the following shortcomings. (1) For the quality exhibited by the involved articles, the sample size of some involved articles was low, and some research

				pla	cebo/a	ctive						
	ep	lereno	ne		contro	l	Weight	Mean Difference	Mear	1 Differer	ice	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, Fixed, 95% CI	IV, Fi	xed, 95%	CI	
1.8.1 eplerenone vs p	placebo	)										
Ando 2014	4.32	0.4068	162	4.16	0.6826	5 152	3.7	0.16 [0.03, 0.29]		—		
Boesby 2011	4.4	0.1481	40	4.3	0.1481	40	13.8	0.10 [0.04, 0.16]			_	
Boesby 2013	4.6	0.6	22	4.4	0.6	24	0.5	0.20 [-0.15, 0.55]				$\longrightarrow$
Jacobsen 2020	4.33	0.62	70	4.07	0.64	70	1.3	0.26 [0.05, 0.47]			<u>.</u>	
Subtotal (95% CI)			294			286	19.3	0.13 [0.07, 0.18]				
Heterogeneity: Chi <sup>2</sup> Test for overall effec	= 2.66, t: <i>Z</i> = 4	df = 3 .47 (P <	(P = 0.45) < 0.00001	); $I^2 = 0\%$								
1.8.2 eplerenone vs t	hiazide	e diuret	ic									
Joffe 2007	4.2	0.4	8	4.1	0.3	8	0.5	0.10 [-0.25, 0.45]		<u> </u>		
Karashima 2016	4.3	0.1	25	4.1	0.1	25	18.9	0.20 [0.14, 0.26]				
Sawai 2017	4.24	0.46	98	4.13	0.41	97	3.9	0.11 [-0.01, 0.23]		-		
Subtotal (95% CI)			131			130	23.2	0.18 [0.13, 0.23]		· ·	<b>•</b>	
Heterogeneity: Chi <sup>2</sup>	= 1.95,	df = 2	(P = 0.38)	); $I^2 = 0\%$								
Test for overall effec	t: $Z = 7$	.17 (P <	< 0.00001	)								
1.8.3 eplerenone vs l	RAS blo	ockers										
Lizakowski 2013-1	4.28	0.08	18	4.45	0.1	18	16.6	-0.17 [-0.23, -0.11]				
Lizakowski 2013-2	4.28	0.08	18	4.56	0.13	18	11.7	-0.28 [-0.35, -0.21]				
Mokadem 2020	4.38	0.44	24	4.44	0.42	23	1.0	-0.06 [-0.31, 0.19]			_	
Tylick 2012-1	4.28	0.08	18	4.56	0.13	18	11.7	-0.28 [-0.35, -0.21]				
Tylick 2012-2	4.28	0.08	18	4.45	0.1	18	16.6	-0.17 [-0.23, -0.11]	_ <b>_</b> _			
Subtotal (95% CI)			96			95	57.5	-0.21 [-0.24, -0.18]	•			
Heterogeneity: Chi2	= 12.48	8, df = 4	P = 0.0	1); $I^2 = 68^{\circ}$	%							
Test for overall effec	t: $Z = 1$	3.13 (P	< 0.0000	1)								
Total (95% CI)			521			511	100.0	-0.06 [-0.08, -0.03]		•		
Heterogeneity: Chi2	= 240.3	33, df =	11 (P < 0)	).00001); I	$^{2} = 95\%$	ó				·		
Test for overall effec	t: $Z = 4$	.53 (P <	< 0.00001	)				-0.5	-0.25	0	0.25	0.5
Test for subgroup di	fference	es: Chi <sup>2</sup>	= 223.24	df = 2 (F)	< 0.00	001), 1	$^{2} = 99.1\%$	, 0	eplerenone	placebo	o (active co	ontrol)

FIGURE 6: Forest plots of the effect on serum potassium levels in articles between the eplerenone treatment groups and the control group. The black diamond indicates summary information with the center of the estimate pooled with the median difference, and the width covers the relevant 95% CIs.

data was insufficient. (2) Only 13 articles (68.5%) were double-blind controlled articles, and only 36.8% of the articles mentioned allocation concealment. (3) In some articles, the observation period and follow-up period were short, thereby impacting the outcome indicators and making it unlikely for evaluating the effectiveness and safety in the long term. For this reason, more high-quality, large-sample randomized controlled clinical articles should be performed subsequently for further clarifying the effectiveness and safety of eplerenone for CKD cases.

	eplere	none	placebo/act	ve control	Weight	Risk Ratio	Ri	sk Ratio	<u> </u>
Study or Subgroup	Events	Total	Events	Total	(%)	M-H, Fixed, 95% Cl	M-H, I	fixed, 95% Cl	
1.5.1 eplerenone vs placeb	00								
Ando 2014	0	162	0	152		Not estimable			
Boesby 2011	1	40	1	40	0.9	1.00 [0.06, 15.44]		_	
Boesby 2013	3	22	2	24	1.8	1.64 [0.30, 8.90]			
Epstein 2006-1	2	89	1	88	0.9	1.98 [0.18, 21.42]			
Epstein 2006-2	3	82	1	88	0.9	3.22 [0.34, 30.34]	_		-
Eschalier 2013	158	1336	96	1340	89.4	1.65 [1.30, 2.10]			
Jacobsen 2020	6	70	2	70	1.9	3.00 [0.63, 14.36]		+	
Subtotal (95% CI)		1801		1802	95.8	1.69 [1.34, 2.13]		•	
Total events	173		103						
Heterogeneity: $Chi^2 = 1.0$	3, df = 5	(P = 0.1)	96); $I^2 = 0\%$						
Test for overall effect: $Z =$	4.40 (P	< 0.000	1)						
1.5.2 eplerenone vs thiazi	de diure	tic							
Joffe 2007	1	8	1	8	0.9	1.00 [0.07, 13.37]			
Sawai 2017	2	117	0	121	0.5	5.17 [0.25, 106.55]			
Subtotal (95% CI)		125		129	1.4	2.37 [0.37, 15.16]	-		
Total events	3		1						
Heterogeneity: Chi <sup>2</sup> = 0.6	8, $df = 1$	(P = 0.4)	41); $I^2 = 0\%$						
Test for overall effect: $Z =$	0.91 (P	= 0.36)							
1.5.3 eplerenone vs RAS b	olockers								
Mokadem 2020	1	25	1	25	0.9	1.00 [0.07, 15.12]			
Subtotal (95% CI)		25		25	0.9	1.00 [0.07, 15.12]			
Total events	1		1						
Heterogeneity: Not applic	able								
Test for overall effect: $Z =$	0.00 (P	= 1.00)							
1.5.4 eplerenone vs CCBs									
White 2003	4	134	2	135	1.9	2.01 [0.38, 10.82]	_		
Subtotal (95% CI)		134		135	1.9	2.01 [0.38, 10.82]	-		
Total events	4		2						
Heterogeneity: Not applic	able								
Test for overall effect: $Z =$	0.82 (P	= 0.41)							
Total (95% CI)		2085		2091	100.0	1.70 [1.35, 2.13]		•	
Total events	181		107						
Heterogeneity: $Chi^2 = 1.9$	0, df = 9	(P = 0.5)	99); $I^2 = 0\%$						
Test for overall effect: Z =	4.54 (P	< 0.000	01)			0.01	0.1		100
Test for subgroup differen	ices: Chi	$^{2} = 0.31$	, $df = 3 (P = 0)$	$(0.96), I^2 = 0$	%		epierenone	placebo (active c	ontrol)



	eplere	none	placebo/acti	ive control	Weight	Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	(%)	M-H, Fixed, 95% CI	M-H, Fixed, 95%	, CI
1.6.1 eplerenone vs placeb	00							
Boesby 2011	0	40	0	40		Not estimable		
Boesby 2013	0	22	0	24		Not estimable		
Epstein 2006-1	2	89	3	88	8.7	0.66 [0.11, 3.85]		
Epstein 2006-2	5	82	3	88	8.3	1.79 [0.44, 7.25]		
Eschalier 2013	33	1336	25	1340	71.9	1.32 [0.79, 2.21]		
Subtotal (95% CI)		1569		1580	89.0	1.30 [0.82, 2.07]		
Total events	40		31					
Heterogeneity: $Chi^2 = 0.72$	7, df = 2	(P = 0.6)	58); $I^2 = 0\%$					
Test for overall effect: $Z =$	1.12 (P =	= 0.26)						
1.6.2 eplerenone vs RAS b	lockers							
Epstein 2002	8	67	2	74	5.5	4.42 [0.97, 20.08]		
Pitt 2003	7	50	2	54	5.5	3.78 [0.82, 17.35]		
Subtotal (95% CI)		117		128	11.0	4.10 [1.40, 11.99]		
Total events	15		4					-
Heterogeneity: $Chi^2 = 0.02$	2, df = 1	(P = 0.8)	$(39); I^2 = 0\%$					
Test for overall effect: $Z =$	2.57 (P =	= 0.01)						
Total (95% CI)		1686		1708	100.0	1.61 [1.06, 2.44]		
Total events	55		35				-	
Heterogeneity: $Chi^2 = 4.43$	8. $df = 4$	(P = 0.3)	$(35): I^2 = 11\%$			Г <u> </u>		
Test for overall effect: $Z =$	2.25 (P =	= 0.02)	.,, ==			0.05	0.2 1	5 20
Test for subgroup differen	ces: Chi <sup>2</sup>	$^{2} = 3.69$	df = 1 (P = 0)	$(0.05), I^2 = 7$	2.9%		eplerenone placebo	(active control)

(b)

FIGURE 7: (a) Incidence of hyperkalemia ( $\geq$ 5.5 mmol/l) in articles comparing eplerenone to placebo/active control. (b) Incidence of hyperkalemia ( $\geq$ 6.0 mmol/l) in articles comparing eplerenone to placebo/active control. The black diamond represents summary data with the center of the estimate pooled with the risk ratio, and the width covers the corresponding 95% CIs.



FIGURE 8: Funnel plots of the effects of eplerenone treatment on (a) 24-h proteinuria. (b) Systolic pressure. (c) UACR. (d) eGFR.

## 5. Conclusion

In brief, this study suggested that eplerenone is capable of effectively lowering protein excretion in CKD cases and that it impacts blood pressure, with the blood creatinine kept stable during the treatment. But it can, to a certain extent, upregulate the blood potassium level and elevate the risk of hyperkalemia. So we need to screen the renal function and blood potassium level before treatment and formulate the drug treatment dose by complying with the principle of individualization. Thus, eplerenone can act as an effective supplement to the existing clinical treatment of cases suffering chronic kidney disease, but its long-term clinical efficacy and safety need to be further confirmed.

#### **Data Availability**

The clinical data of the population used to support the findings of this study are available from the corresponding author upon request.

## **Conflicts of Interest**

The authors declare that there are no conflicts of interest in this manuscript.

## **Authors' Contributions**

Honglei Hu and Mengdie Cao contributed equally to this manuscript.

### Acknowledgments

The authors would like to thank the authors of the articles for their contributions to this study. This manuscript was supported by the Project of Invigorating Healthcare through the Science and Technology Program of Suzhou Municipal Science and Technology Bureau (No. KJXW2021029).

#### References

- J. C. Lv and L. X. Zhang, "Prevalence and disease burden of chronic kidney disease," Advances in Experimental Medicine and Biology, vol. 1165, pp. 3–15, 2019.
- [2] H. Hu, X. Zhao, X. Jin, S. Wang, W. Liang, and X. Cong, "Efficacy and safety of eplerenone treatment for patients with diabetic nephropathy: a meta-analysis," *PLoS One*, vol. 17, no. 3, Article ID 265642, 2022.
- [3] H. Minakuchi, S. Wakino, H. Urai et al., "The effect of aldosterone and aldosterone blockade on the progression of chronic kidney disease: a randomized placebo-controlled clinical trial," *Scientific Reports*, vol. 10, no. 1, Article ID 16626, 2020.
- [4] N. Vodošek Hojs, S. Bevc, R. Ekart, N. Piko, T. Petreski, and R. Hojs, "Mineralocorticoid receptor antagonists in diabetic kidney disease," *Pharmaceuticals*, vol. 14, no. 6, Article ID 14060, 2021.
- [5] D. Moher, A. Liberati, J. Tetzlaff, and D. G. Altman, "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement," *PLoS Medicine*, vol. 6, no. 7, Article ID 1000097, 2009.
- [6] M. Epstein, G. H. Williams, M. Weinberger et al., "Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes," *Clinical Journal of the American Society of Nephrology*, vol. 1, no. 5, pp. 940–951, 2006.
- [7] H. V. Joffe, R. Y. Kwong, M. D. Gerhard-Herman, C. Rice, K. Feldman, and G. K. Adler, "Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus," *Journal of Clinical Endocrinology and Metabolism*, vol. 92, no. 7, pp. 2552–2558, 2007.
- [8] J. J. Kovarik, C. C. Kaltenecker, O. Domenig et al., "Effect of mineralocorticoid receptor antagonism and ACE inhibition on angiotensin profiles in diabetic kidney disease: an exploratory study," *Diabetes Therapy*, vol. 12, no. 9, pp. 2485– 2498, 2021.
- [9] L. Boesby, T. Elung-Jensen, S. Strandgaard, and A. L. Kamper, "Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4--a randomized controlled study," *PLoS One*, vol. 8, no. 5, Article ID 64549, 2013.
- [10] N. H. Brandt-Jacobsen, M. L. Johansen, J. Rasmussen et al., "Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: data from the MIRAD trial," *Diabetes and Metabolism*, vol. 47, no. 4, Article ID 101190, 2021.
- [11] M. El Mokadem, Y. Abd El Hady, and A. Aziz, "A prospective single-blind randomized trial of ramipril, eplerenone and their combination in type 2 diabetic nephropathy," *Cardiorenal Med*, vol. 10, no. 6, pp. 392–401, 2020.
- [12] S. Karashima, T. Yoneda, M. Kometani et al., "Angiotensin II receptor blocker combined with eplerenone or hydrochlorothiazide for hypertensive patients with diabetes mellitus," *Clinical and Experimental Hypertension*, vol. 38, no. 7, pp. 565–570, 2016.

- [13] M. Epstein, V. Buckalew, F. Martinez et al., "OR-54: antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/ enalapril combination therapy in diabetic hypertensives with microalbuminuria," *American Journal of Hypertension*, vol. 15, no. 4, p. 24, 2002.
- [14] T. Sawai, K. Dohi, N. Fujimoto et al., "Antialbuminuric effect of eplerenone in comparison to thiazide diuretics in patients with hypertension," *Journal of Clinical Hypertension*, vol. 19, no. 10, pp. 990–998, 2017.
- [15] K. Ando, H. Ohtsu, S. Uchida, S. Kaname, Y. Arakawa, and T. Fujita, "Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial," *Lancet Diabetes and Endocrinology*, vol. 2, no. 12, pp. 944–953, 2014.
- [16] L. Boesby, T. Elung-Jensen, T. W. Klausen, S. Strandgaard, and A. L. Kamper, "Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study," *PLoS One*, vol. 6, no. 11, Article ID 26904, 2011.
- [17] R. Eschalier, J. J. McMurray, K. Swedberg et al., "Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHA-SIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart Failure)," *Journal of the American College of Cardiology*, vol. 62, no. 17, pp. 1585–1593, 2013.
- [18] L. Tylicki, S. Lizakowski, P. Rutkowski et al., "The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?" *Kidney and Blood Pressure Research*, vol. 36, no. 1, pp. 335–343, 2012.
- [19] S. Lizakowski, L. Tylicki, P. Rutkowski et al., "Safety of enhanced renin-angiotensin-aldosterone system inhibition with aliskiren in nondiabetic patients with chronic kidney disease," *Polish Archives of Internal Medicine*, vol. 123, no. 5, pp. 221–227, 2013.
- [20] T. Kalizki, B. M. W. Schmidt, U. Raff et al., "Low doseeplerenone treatment decreases aortic stiffness in patients with resistant hypertension," *Journal of Clinical Hypertension*, vol. 19, no. 7, pp. 669–676, 2017.
- [21] W. B. White, D. Duprez, R. St Hillaire et al., "Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension," *Hypertension*, vol. 41, no. 5, pp. 1021–1026, 2003.
- [22] G. H. Williams, E. Burgess, R. E. Kolloch et al., "Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension," *The American Journal of Cardiology*, vol. 93, no. 8, pp. 990–996, 2004.
- [23] B. Pitt, N. Reichek, R. Willenbrock et al., "Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study," *Circulation*, vol. 108, no. 15, pp. 1831–1838, 2003.
- [24] K. Eguchi, T. Kabutoya, S. Hoshide, S. Ishikawa, and K. Kario, "Add-on use of eplerenone is effective for lowering home and ambulatory blood pressure in drug-resistant hypertension," *Journal of Clinical Hypertension*, vol. 18, no. 12, pp. 1250– 1257, 2016.
- [25] X. Guo, S. Liang, W. Wang et al., "Lowest nocturnal systolic blood pressure is related to heavy proteinuria and outcomes in elderly patients with chronic kidney disease," *Scientific Reports*, vol. 11, no. 1, p. 5846, 2021.
- [26] S. J. Schrauben, H. Y. Chen, E. Lin et al., "Hospitalizations among adults with chronic kidney disease in the

United States: a cohort study," *PLoS Medicine*, vol. 17, no. 12, Article ID 1003470, 2020.

- [27] J. B. Wish and P. Pergola, "Evolution of mineralocorticoid receptor antagonists in the treatment of chronic kidney disease associated with type 2 diabetes mellitus," *Mayo Clinic Proceedings: Innovations, Quality and Outcomes*, vol. 6, no. 6, pp. 536–551, 2022.
- [28] V. Patel, A. Joharapurkar, and M. Jain, "Role of mineralocorticoid receptor antagonists in kidney diseases," *Drug Development Research*, vol. 82, no. 3, pp. 341–363, 2021.
- [29] Y. Miyagawa, R. Akabane, A. Sakatani et al., "Effects of telmisartan on proteinuria and systolic blood pressure in dogs with chronic kidney disease," *Research in Veterinary Science*, vol. 133, pp. 150–156, 2020.
- [30] R. E. Schmieder, J. F. E. Mann, H. Schumacher et al., "Changes in albuminuria predict mortality and morbidity in patients with vascular disease," *Journal of the American Society of Nephrology*, vol. 22, no. 7, pp. 1353–1364, 2011.
- [31] D. de Zeeuw, G. Remuzzi, H. H. Parving et al., "Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL," *Kidney International*, vol. 65, no. 6, pp. 2309–2320, 2004.
- [32] C. Zuo and G. Xu, "Efficacy and safety of mineralocorticoid receptor antagonists with ACEI/ARB treatment for diabetic nephropathy: a meta-analysis," *International Journal of Clinical Practice*, vol. 73, no. 12, Article ID 13413, 2019.
- [33] K. Ando, K. Nitta, H. Rakugi et al., "Comparison of the antialbuminuric effects of benidipine and hydrochlorothiazide in renin-angiotensin system (RAS) inhibitor-treated hypertensive patients with albuminuria: the COSMO-CKD (COmbination strategy on renal function of benidipine or diuretics TreatMent with RAS inhibitOrs in a chronic kidney disease hypertensive population) study," *International Journal* of Medical Sciences, vol. 11, no. 9, pp. 897–904, 2014.
- [34] T. Hoshino, S. Ookawara, H. Miyazawa et al., "Renoprotective effects of thiazides combined with loop diuretics in patients with type 2 diabetic kidney disease," *Clinical and Experimental Nephrology*, vol. 19, no. 2, pp. 247–253, 2015.
- [35] N. M. Selby and M. W. Taal, "An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines," *Diabetes, Obesity and Metabolism*, vol. 22, no. 1, pp. 3–15, 2020.
- [36] L. J. Sun, Y. N. Sun, J. P. Shan, and G. R. Jiang, "Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy," *Journal Diabetes Investig*, vol. 8, no. 4, pp. 609–618, 2017.
- [37] S. Takahashi, M. Hiramatsu, S. Hotta et al., "Safety and antihypertensive effect of Selara<sup>®</sup> (eplerenone): results from a postmarketing surveillance in Japan," *International Journal* of Hypertension, vol. 2016, Article ID 5091951, 9 pages, 2016.
- [38] G. Derosa, G. Gaudio, G. Pasini, A. D'Angelo, and P. Maffioli, "A randomized, double-blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients," *Drug Design, Development and Therapy*, vol. 12, pp. 2611–2616, 2018.
- [39] N. Sato, M. Ajioka, T. Yamada et al., "A randomized controlled study of finerenone vs. Eplerenone in Japanese patients with worsening chronic heart failure and diabetes and/or chronic kidney disease," *Circulation Journal*, vol. 80, no. 5, pp. 1113–1122, 2016.
- [40] J. P. Ferreira, P. Abreu, J. J. V. McMurray et al., "Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial," *European Journal of Heart Failure*, vol. 21, no. 3, pp. 345–351, 2019.